Annual EBIT
-$159.62 M
+$10.79 M+6.33%
December 31, 2023
Summary
- As of February 7, 2025, PHAT annual earnings before interest & taxes is -$159.62 million, with the most recent change of +$10.79 million (+6.33%) on December 31, 2023.
- During the last 3 years, PHAT annual EBIT has fallen by -$35.14 million (-28.23%).
- PHAT annual EBIT is now -12419.53% below its all-time high of -$1.27 million, reached on December 31, 2018.
Performance
PHAT EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$67.09 M
+$6.59 M+8.94%
September 30, 2024
Summary
- As of February 7, 2025, PHAT quarterly earnings before interest & taxes is -$67.09 million, with the most recent change of +$6.59 million (+8.94%) on September 30, 2024.
- Over the past year, PHAT quarterly EBIT has increased by +$6.59 million (+8.94%).
- PHAT quarterly EBIT is now -23359.09% below its all-time high of -$286.00 thousand, reached on September 30, 2018.
Performance
PHAT Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$273.00 M
-$33.96 M-14.21%
September 30, 2024
Summary
- As of February 7, 2025, PHAT TTM earnings before interest & taxes is -$273.00 million, with the most recent change of -$33.96 million (-14.21%) on September 30, 2024.
- Over the past year, PHAT TTM EBIT has dropped by -$33.96 million (-14.21%).
- PHAT TTM EBIT is now -95354.55% below its all-time high of -$286.00 thousand, reached on September 30, 2018.
Performance
PHAT TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
PHAT EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +6.3% | +8.9% | -14.2% |
| 3 y3 years | -28.2% | -47.6% | -60.2% |
| 5 y5 years | -10000.0% | -47.6% | -60.2% |
PHAT EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -16.4% | +6.3% | -134.6% | +8.9% | -99.1% | at low |
| 5 y | 5-year | -28.2% | +36.4% | -245.8% | +30.8% | -119.3% | at low |
| alltime | all time | <-9999.0% | +36.4% | <-9999.0% | +30.8% | <-9999.0% | at low |
Phathom Pharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$67.09 M(-8.9%) | -$273.00 M(+14.2%) |
| Jun 2024 | - | -$73.68 M(+12.2%) | -$239.04 M(+21.5%) |
| Mar 2024 | - | -$65.68 M(-1.3%) | -$196.71 M(+23.2%) |
| Dec 2023 | -$159.62 M(-6.3%) | -$66.54 M(+100.8%) | -$159.62 M(+15.2%) |
| Sep 2023 | - | -$33.14 M(+5.7%) | -$138.53 M(-5.9%) |
| Jun 2023 | - | -$31.35 M(+9.6%) | -$147.21 M(-8.6%) |
| Mar 2023 | - | -$28.60 M(-37.1%) | -$161.11 M(-5.5%) |
| Dec 2022 | -$170.42 M(+24.3%) | -$45.45 M(+8.7%) | -$170.42 M(+7.8%) |
| Sep 2022 | - | -$41.81 M(-7.6%) | -$158.02 M(+4.4%) |
| Jun 2022 | - | -$45.25 M(+19.4%) | -$151.39 M(+7.0%) |
| Mar 2022 | - | -$37.91 M(+14.7%) | -$141.43 M(+3.2%) |
| Dec 2021 | -$137.09 M | -$33.05 M(-6.0%) | -$137.09 M(-12.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | -$35.18 M(-0.3%) | -$156.47 M(+1.5%) |
| Jun 2021 | - | -$35.30 M(+5.1%) | -$154.11 M(+11.1%) |
| Mar 2021 | - | -$33.57 M(-36.0%) | -$138.66 M(+11.4%) |
| Dec 2020 | -$124.49 M(-50.4%) | -$52.43 M(+59.7%) | -$124.49 M(-26.4%) |
| Sep 2020 | - | -$32.82 M(+65.4%) | -$169.03 M(-16.5%) |
| Jun 2020 | - | -$19.84 M(+2.2%) | -$202.33 M(-24.8%) |
| Mar 2020 | - | -$19.40 M(-80.0%) | -$269.12 M(+7.2%) |
| Dec 2019 | -$250.95 M(>+9900.0%) | -$96.97 M(+46.6%) | -$250.95 M(+62.5%) |
| Sep 2019 | - | -$66.12 M(-23.7%) | -$154.47 M(+74.3%) |
| Jun 2019 | - | -$86.63 M(+6885.9%) | -$88.63 M(+4320.4%) |
| Mar 2019 | - | -$1.24 M(+158.9%) | -$2.00 M(+162.1%) |
| Dec 2018 | -$1.27 M | -$479.00 K(+67.5%) | -$765.00 K(+167.5%) |
| Sep 2018 | - | -$286.00 K | -$286.00 K |
FAQ
- What is Phathom Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for Phathom Pharmaceuticals?
- What is Phathom Pharmaceuticals annual EBIT year-on-year change?
- What is Phathom Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Phathom Pharmaceuticals?
- What is Phathom Pharmaceuticals quarterly EBIT year-on-year change?
- What is Phathom Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Phathom Pharmaceuticals?
- What is Phathom Pharmaceuticals TTM EBIT year-on-year change?
What is Phathom Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of PHAT is -$159.62 M
What is the all time high annual EBIT for Phathom Pharmaceuticals?
Phathom Pharmaceuticals all-time high annual earnings before interest & taxes is -$1.27 M
What is Phathom Pharmaceuticals annual EBIT year-on-year change?
Over the past year, PHAT annual earnings before interest & taxes has changed by +$10.79 M (+6.33%)
What is Phathom Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of PHAT is -$67.09 M
What is the all time high quarterly EBIT for Phathom Pharmaceuticals?
Phathom Pharmaceuticals all-time high quarterly earnings before interest & taxes is -$286.00 K
What is Phathom Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, PHAT quarterly earnings before interest & taxes has changed by +$6.59 M (+8.94%)
What is Phathom Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of PHAT is -$273.00 M
What is the all time high TTM EBIT for Phathom Pharmaceuticals?
Phathom Pharmaceuticals all-time high TTM earnings before interest & taxes is -$286.00 K
What is Phathom Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, PHAT TTM earnings before interest & taxes has changed by -$33.96 M (-14.21%)